Ramipril and Losartan Exert a Similar Long-Term Effect upon Markers of Heart Failure, Endogenous Fibrinolysis, and Platelet Aggregation in Survivors of ST-Elevation Myocardial Infarction: A Single Centre Randomized Trial

Table 1

Baseline clinical and laboratory data of all STEMI patients and comparisons between patients treated with ramipril and losartan.

Baseline clinical and laboratory data	All patients; ()	Ramipril; ()	Losartan; ()
Mean age ± SD (years)	58.7 ± 9.9	59.1 ± 11.2	58.3 ± 8.4	0.774
Mean BMI ± SD	27.4 ± 4.3	26.9 ± 3.4	27.8 ± 5.0	0.447
Mean peak TnI ± SD (μg/L)	45.3 ± 38.5	42.2 ± 37.7	48.4 ± 39.9	0.553
Mean admission TnI ± SD (µg/L)	4.0 ± 8.1	4.6 ± 8.5	3.4 ± 7.7	0.588
Time to PPCI ± SD (hours)	4.7 ± 3.8	5.4 ± 4.2	4.0 ± 3.1	0.156

STEMI: ST-elevation myocardial infarction; TnI: Troponin I; SD: standard deviation; PPCI: primary percutaneous coronary intervention.